The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
Figlioli G., Bogliolo M., Catucci I., Caleca L., Lasheras SV., Pujol R., Kiiski JI., Muranen TA., Barnes DR., Dennis J., Michailidou K., Bolla MK., Leslie G., Aalfs CM., ABCTB Investigators None., Adank MA., Adlard J., Agata S., Cadoo K., Agnarsson BA., Ahearn T., Aittomäki K., Ambrosone CB., Andrews L., Anton-Culver H., Antonenkova NN., Arndt V., Arnold N., Aronson KJ., Arun BK., Asseryanis E., Auber B., Auvinen P., Azzollini J., Balmaña J., Barkardottir RB., Barrowdale D., Barwell J., Beane Freeman LE., Beauparlant CJ., Beckmann MW., Behrens S., Benitez J., Berger R., Bermisheva M., Blanco AM., Blomqvist C., Bogdanova NV., Bojesen A., Bojesen SE., Bonanni B., Borg A., Brady AF., Brauch H., Brenner H., Brüning T., Burwinkel B., Buys SS., Caldés T., Caliebe A., Caligo MA., Campa D., Campbell IG., Canzian F., Castelao JE., Chang-Claude J., Chanock SJ., Claes KBM., Clarke CL., Collavoli A., Conner TA., Cox DG., Cybulski C., Czene K., Daly MB., de la Hoya M., Devilee P., Diez O., Ding YC., Dite GS., Ditsch N., Domchek SM., Dorfling CM., Dos-Santos-Silva I., Durda K., Dwek M., Eccles DM., Ekici AB., Eliassen AH., Ellberg C., Eriksson M., Evans DG., Fasching PA., Figueroa J., Flyger H., Foulkes WD., Friebel TM., Friedman E., Gabrielson M., Gaddam P., Gago-Dominguez M., Gao C., Gapstur SM., Garber J., García-Closas M., García-Sáenz JA., Gaudet MM., Gayther SA., GEMO Study Collaborators None., Giles GG., Glendon G., Godwin AK., Goldberg MS., Goldgar DE., Guénel P., Gutierrez-Barrera AM., Haeberle L., Haiman CA., Håkansson N., Hall P., Hamann U., Harrington PA., Hein A., Heyworth J., Hillemanns P., Hollestelle A., Hopper JL., Hosgood HD., Howell A., Hu C., Hulick PJ., Hunter DJ., Imyanitov EN., KConFab None., Isaacs C., Jakimovska M., Jakubowska A., James P., Janavicius R., Janni W., John EM., Jones ME., Jung A., Kaaks R., Karlan BY., Khusnutdinova E., Kitahara CM., Konstantopoulou I., Koutros S., Kraft P., Lambrechts D., Lazaro C., Le Marchand L., Lester J., Lesueur F., Lilyquist J., Loud JT., Lu KH., Luben RN., Lubinski J., Mannermaa A., Manoochehri M., Manoukian S., Margolin S., Martens JWM., Maurer T., Mavroudis D., Mebirouk N., Meindl A., Menon U., Miller A., Montagna M., Nathanson KL., Neuhausen SL., Newman WG., Nguyen-Dumont T., Nielsen FC., Nielsen S., Nikitina-Zake L., Offit K., Olah E., Olopade OI., Olshan AF., Olson JE., Olsson H., Osorio A., Ottini L., Peissel B., Peixoto A., Peto J., Plaseska-Karanfilska D., Pocza T., Presneau N., Pujana MA., Punie K., Rack B., Rantala J., Rashid MU., Rau-Murthy R., Rennert G., Lejbkowicz F., Rhenius V., Romero A., Rookus MA., Ross EA., Rossing M., Rudaitis V., Ruebner M., Saloustros E., Sanden K., Santamariña M., Scheuner MT., Schmutzler RK., Schneider M., Scott C., Senter L., Shah M., Sharma P., Shu X-O., Simard J., Singer CF., Sohn C., Soucy P., Southey MC., Spinelli JJ., Steele L., Stoppa-Lyonnet D., Tapper WJ., Teixeira MR., Terry MB., Thomassen M., Thompson J., Thull DL., Tischkowitz M., Tollenaar RAEM., Torres D., Troester MA., Truong T., Tung N., Untch M., Vachon CM., van Rensburg EJ., van Veen EM., Vega A., Viel A., Wappenschmidt B., Weitzel JN., Wendt C., Wieme G., Wolk A., Yang XR., Zheng W., Ziogas A., Zorn KK., Dunning AM., Lush M., Wang Q., McGuffog L., Parsons MT., Pharoah PDP., Fostira F., Toland AE., Andrulis IL., Ramus SJ., Swerdlow AJ., Greene MH., Chung WK., Milne RL., Chenevix-Trench G., Dörk T., Schmidt MK., Easton DF., Radice P., Hahnen E., Antoniou AC., Couch FJ., Nevanlinna H., Surrallés J., Peterlongo P.
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.